CRA’s Rare Disease Spotlight team is excited to present Project LEOPARD, an ongoing assessment of the long-term evolution and outlook for patient access in rare disease. In this first installment, Cécile Matthews and Bhavesh Patel explore what we can expect for patient access in established, or competitive, rare diseases, and how life sciences companies can successfully navigate the future environment for this category of rare disease. Learn more about Project LEOPARD and subscribe to our rare disease insights.
Part 2: Low-priced oncology disruptors: The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Healthcare coverage is heterogeneous across emerging markets, with public funding limited by budgetary constraints. This typically sees higher-priced drugs,...